ImmunoGen, Inc. (IMGN) announced that results from the phase II STARLYTE study on SAR3419 (coltuximab ravtansine) were presented at the 50th annual meeting of American Society of Clinical Oncology (TATD). ImmunoGen has an agreement with Sanofi (SNY), as per which SAR3419 is developed by ImmunoGen and licensed to Sanofi. SAR3419 is a CD19-targeting antibody-drug conjugate (ADC).
The STARLYTE study is evaluating the efficacy and safety of SAR3419 as a single agent for the treatment of relapsed or relapsed/refractory CD19-positive diffuse large B-cell lymphoma (:DLBCL). Patients enrolled for the study received SAR3419 (55 mg/m2) on a weekly basis for four weeks and then every other week till the time of disease progression or discontinuation.
Data presented at ASCO revealed that SAR3419 achieved a 43.9% objective response rate (ORR.V) for the per protocol population (patients suffering from relapsed or relapsed/refractory DLBCL). The primary objective of the STARLYTE study is to evaluate whether SAR3419 treatment results in an ORR of at least 20% in the patient population. Data also suggests that SAR3419 demonstrated a favorable safety profile.
We note that SAR3419 is also being developed for the treatment of B-cell acute lymphoblastic leukemia. ImmunoGen has progressed well with its pipeline in the last few quarters.
The company also has multiple pipeline related events in the coming quarters and we expect investors focus to remain on these events. Moreover, we are also encouraged by ImmunoGen’s alliances with big companies. Apart from Sanofi, ImmunoGen has agreements with companies like Novartis (NVS).
ImmunoGen presently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Zacks Ranked #2 (Buy) Ariad Pharmaceuticals Inc. (ARIA).